Table 1.
Undertaken case reports in the treatment of ulcerative colitis (UC) by various sources of MSCs.
| Type of Study | Stem Cell Source (n) | Outcome | Reference |
|---|---|---|---|
| Case report | BMSCs (4.0 × 108 cells, volume: 50 mL, submucosal injection) | Alleviation of UC symptoms, recovering from hematochezia, decrease in C reactive protein and lesions, bleeding, and edema in the sigmoid colon and rectum. | [53] |
| Case report | BMSCs (NA) | The first IV systemic cell transplantation and successful treatment of UC. | [54] |
| Case series | BMSCs (NA) | Improvement in clinical course, increase in duration of remission, and decrease in the risk of relapse. | [55] |
| Case series | BMSCs (NA) | Improvement in clinical course and decline in risk of relapse and frequency of hospital admissions after 2 years of follow-up. | [56] |
| Case series | BMSCs (NA) | Age as a prognostic factor in effective treatment of patients; in the elderly, the transplantation was less effective. | [57] |
| Case report | HSCs (NA) | Complete resolution of a severe form of UC. | [59] |
| Case series | BMSCs (NA) | Allogeneic BMSCs were safe and contributed to clinical improvement in patients with refractory UC. | [60] |
MSCs: Mesenchymal stem cells. BMSCs: Bone marrow-derived stem cells. HSCs: Hematopoietic stem cells. NA: Not available. IV: Intravenously.